Previous 10 |
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Cable One, Inc. (NYSE:CAB...
– Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful therapies, Avastin and Rituxan, during his tenure...
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company’s Prior Approval Supplement (PAS) filing for the large-scale Ge...
Portola Pharmaceuticals (NASDAQ: PTLA ) announces that Tao Fu, Chief Commercial Officer, has resigned effective September 21 to pursue opportunities outside the Company. A search for a successor is underway. More news on: Portola Pharmaceuticals, Healthcare stocks news, Read mor...
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective September 21, 2018 to pursue opportunities outside the Company. The Company has engaged a lead...
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of Directors approved, effective as of August 31, 2018, the grant of an inducement stock optio...
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
NASDAQ Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...